Anti-VEGF therapies have been reported to increase the secretion of alternative factors such as VEGF-D, ANG-2, PDGF, PIGF, VEGF-C, and SDF1-α in the blood of cancer patients [8,12,16]. The gene discussed is VEGFA; the disease is cancer.